VUF11207|CAS 1378524-41-4|DC Chemicals

VUF11207|CAS 1378524-41-4|DC Chemicals

VUF11207 is a highly potent CXCR7 agonist. VUF11207 induces recruitment of β-arrestin2 to the CXCR7 followed by internalization of the receptor.

Product Name: VUF11207|Cat No.:DC8851|CAS: 1378524-41-4|Other names: VUF11207，VUF-11207，VUF 11207|MW: 470.58|C27H35FN2O4

VUF11207 is a highly potent CXCR7 agonist. VUF11207 induces recruitment of β-arrestin2 to the CXCR7 followed by internalization of the receptor.

For research only, not for human use!

ML-213(CID-3111211)|CAS 489402-47-3|DC Chemicals

ML-213(CID-3111211)|CAS 489402-47-3|DC Chemicals

ML-213 (CID-3111211)  is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener (EC50 values are 230 and 510 nM for KV7.2 and KV7.4 respectively).

Product Name: ML-213(CID-3111211)|Cat No.:DC8850|CAS: 489402-47-3|Other names: ML213,ML 213,CID 3111211,CID3111211|MW: 257.37|C17H23NO

Selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener (EC50 values are 230 and 510 nM for KV7.2 and KV7.4 respectively). Displays > 80-fold selectivity against KV7.1, KV7.3 and KV7.5 in a thallium-based fluorescence assay.

For research only, not for human use!

CID-2858522|cas 758679-97-9|DC Chemicals

CID-2858522|cas 758679-97-9|DC Chemicals

CID-2858522 is a selectively inhibits protein kinase C (PKC)-induced activation of the NF-κB pathway (IC50 < 0.1 μM for PMA-stimulated IL-8 production). 

Product Name: CID-2858522|Cat No.:DC8849|CAS: 758679-97-9|Other names: CID 2858522,CID2858522|MW: 465.63|C28H39N3O3

Selectively inhibits protein kinase C (PKC)-induced activation of the NF-κB pathway (IC50 < 0.1 μM for PMA-stimulated IL-8 production). Inhibits antigen receptor-stimulated NF-κB activation in chronic lymphocytic leukemia (CLL) B cells. Does not inhibit other NF-κB pathways, including that activated by tumor necrosis factor (TNF).

For research only, not for human use!

Nosiheptide|cas 56377-79-8|DC Chemicals

Nosiheptide|cas 56377-79-8|DC Chemicals

Nosiheptide is a bicyclic thiopeptide antibiotic produced by several species of actinomycetes, notably Streptomyces. 

Product Name: Nosiheptide|cas 56377-79-8|DC Chemicals|Cat No.:DC8848|CAS: 56377-79-8|Other names: |MW: 222.36|C51H43N13O12S6

Nosiheptide is a bicyclic thiopeptide antibiotic produced by several species of actinomycetes, notably Streptomyces. Unlike other bicyclic thiopeptides such as thiostrepton, the second macrocyclic ring is linked by relatively fragile lactone and thiolactone bridges to the core cylic peptide. Nosiheptide has broad spectrum antibacterial activity, and has recently demonstrated a prolonged post-antibiotic effect in both nosocomial and community-acquired MRSA compared with vancomycin.

For research only, not for human use!

Finafloxacin (BAY35-3377)|DC Chemicals

Finafloxacin (BAY35-3377)|DC Chemicals

Finafloxacin hydrochloride, an important clinical compound was synthesized by a novel synthetic approach.

Product Name: Finafloxacin (BAY35-3377)|cas 209342-41-6|DC Chemicals|Cat No.:DC8847|CAS: 209342-41-6|Other names: |MW: 434.85|C20H19FN4O4•HCl

Finafloxacin hydrochloride, an important clinical compound was synthesized by a novel synthetic approach.

For research only, not for human use!

GLI1-Mediated transcription inhibitor|cas 496794-70-8|DC Chemicals

GLI1-Mediated transcription inhibitor|cas 496794-70-8|DC Chemicals

A GLI1-Mediated transcription inhibitor

Product Name: GLI1-Mediated transcription inhibitor|Cat No.:DC8846|CAS: 496794-70-8|Other names: |MW: 450.92|C24H23ClN4O3

A GLI1-Mediated transcription inhibitor

For research only, not for human use!

AMG-337|AMG337|cas 1173699-31-4|DC Chemicals

AMG-337|AMG337|cas 1173699-31-4|DC Chemicals

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.

Product Name: AMG337|Cat No.:DC8845|CAS: 1173699-31-4|Other names: AMG 337,AMG-337|MW: 463.46|C23H22FN7O3

AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.in vitro: AMG-337 demonstrates exquisite selectivity for MET when profiled against a diverse panel of over 400 protein and lipid kinases in a competitive binding assay. In cellular assays, AMG 337 inhibits HGF-dependent MET phosphorylation with an IC50 of < 10 nM. AMG 337 is a selective inhibitor of Met, which inhibits multiple mechanisms of Met activation.

in vivo: AMG-337 demonstrates robust activity in MET-dependent cancer models. Oral administration of AMG 337 results in robust dose-dependent anti-tumor efficacy in MET amplified gastric cancer xenograft models, with inhibition of tumor growth consistent with the pharmacodynamic modulation of MET signaling.

For research only, not for human use!

PCI-27483|PCI27483|cas 871266-63-6|DC Chemicals

PCI-27483|PCI27483|cas 871266-63-6|DC Chemicals

PCI-27483 is a selective small molecule inhibitor of activated coagulation factor VII (FVIIa), which is in preclinical development as a novel anti-cancer agent. 

Product Name: PCI-27483|Cat No.:DC8844|CAS: 871266-63-6  |Other names: PCI27483,PCI-27483,PCI 27483|MW: 596.57|C26H24N6O9S

PCI-27483 is a selective small molecule inhibitor of activated coagulation factor VII (FVIIa), which is in preclinical development as a novel anti-cancer agent. 

For research only, not for human use!

AVN-944(VX-944)|cas 297730-17-7|DC Chemicals

AVN-944(VX-944)|cas 297730-17-7|DC Chemicals

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.

Product Name: AVN 944|Cat No.:DC8843|CAS: 297730-17-7|Other names: AVN-944,AVN 944,AVN944,VX 944,VX944|MW: 477.51|C25H27N5O5

AVN-944(VX-944) is a selective, noncompetitive inhibitor of the enzyme directed against human IMPDH with Ki of 6-10 nM for IMPDH1/IMPDH2.in vitro: AVN-944 strikingly inhibit RNA synthesis within 2 h of exposure. Depletion of guanine nucleotides by MPA and AVN-944 also causes an early and near-complete reduction in levels of the 45S precursor rRNA synthesis and the concomitant translocation of nucleolar proteins including nucleolin, nucleophosmin, and nucleostemin from the nucleolus to the nucleoplasm. AVN944 induced caspase-dependentand caspase-independent cell death in LNCaP, CWR22Rv1, and DU145 cells. AVN944 induced expression of p53-target proteins Bok, Bax and Noxa in androgen-responsive cell lines and suppressed expression of survivin in prostate cancer cells regardless of their androgen sensitivity. AVN944 also induced differentiation of androgen-independent prostate cancer cells as indicated by morphological changes and increased expression of genes coding for prostasomal proteins, keratins and other proteins, including tumor suppressor genes MIG-6 and NDRG1. AVN944-differentiated androgen-independent DU145 and PC-3 cells are sensitized to TRAIL-induced apoptosis as demonstrated by induction of caspases and PARP cleavage.

For research only, not for human use!

AZ-7371|AZ7371|cas 1494675-86-3|DprE1 inhibitor|DC Chemicals

AZ-7371|AZ7371|cas 1494675-86-3|DprE1 inhibitor|DC Chemicals

AZ-7371 is a novel non-covalent DprE1 inhibitor.

Product Name: AZ-7371|Cat No.:DC8842|CAS: 1494675-86-3|Other names: AZ7371,AZ 7371|MW: 355.16|C18H21N5O3

AZ-7371 is a novel non-covalent DprE1 inhibitor.

For research only, not for human use!

Argatroban monohydrate|cas 141396-28-3|DC Chemicals

Argatroban monohydrate|cas 141396-28-3|DC Chemicals

Argatroban monohydrate is a direct, selective thrombin inhibitor.

Product Name: Argatroban monohydrate|Cat No.:DC8841|CAS: 141396-28-3|Other names: Argipidine monohydrate; Acova monohydrate|MW: 526.65|C23H38N6O6S

Argatroban may have a complementary effect for preventing thrombus formation without aggravating bleeding tendency because of its monotarget specificity to thrombin. Administration (0.5 to 2 micrograms/kg/min) of argatroban is a safe anticoagulant for left heart bypass in repairs of traumatic aortic rupture associated with multiple organ injuries. Argatroban, as compared with heparin, appears to enhance reperfusion with TPA in patients with AMI, particularly in those patients with delayed presentation. The incidences of major bleeding and adverse clinical outcome were lower in the patients receiving argatroban.

For research only, not for human use!

CB 5083,CB5083|cas 1542705-92-9|DC Chemicals

CB 5083,CB5083|cas 1542705-92-9|DC Chemicals

CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .

Product Name: CB-5083|Cat No.:DC8840|CAS: 1542705-92-9|Other names: CB 5083,CB5083|MW: 413.4|C24H23N5O2 

CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models . CB-5083 causes rapid and sustained accumulation of poly-ubiquitin in tumor xenografts after a single administration. CB-5083 showed activity to inhibit tumor growth in multiple rodent models of human cancer. Furthermore, CB-5083 appears to exhibit greater potency over current proteasome inhibitors that further validate targeting p97 and protein homeostasis in the treatment of cancer.

For research only, not for human use!

RS-1|CRISPR editing compound|cas 312756-74-4|DC Chemicals

RS-1|CRISPR editing compound|cas 312756-74-4|DC Chemicals

RS-1 is a stimulator of the human homologous recombination protein RAD51, useful compound for CRISPR editing.

Product Name: RS-1|Cat No.:DC8839|CAS: 312756-74-4|Other names: RS1,RS 1|MW: 524.23|C20H16Br2N2O3S

RS-1 is a stimulator of the human homologous recombination protein RAD51, useful compound for CRISPR editing.

For research only, not for human use!

Indirubin|cas 479-41-4|DC Chemicals

Indirubin|cas 479-41-4|DC Chemicals

Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM.

Product Name: Indirubin|Cat No.:DC8838|CAS: 479-41-4|Other names: |MW: 262.26|C16H10N2O2

Indirubin, a bis-indole obtained from various natural sources, is responsible for the reported antileukemia activity of a Chinese Medicinal recipe, Danggui Longhui Wan.A dramatic cytostatic effect, as measured by actual cell counts and associated with a sharp G1 phase arrest, is induced by 1-methyl-indirubins, a subfamily of AhR-active but kinase-inactive indirubins.In the time-course experiment, CYP1A1 mRNA is induced by indirubin transiently. Indirubin was also metabolized by CYP1A1 and lost its ligand activity. Indirubin would appear to be a good substrate of CYP1A1 given its low dissociation constant.Levels of cytochrome P450 1A1/2 proteins and mRNAs in the liver of mice dosed with indirubin were also enhanced.

For research only, not for human use!

AZD-7547|AZD7547|cas 252017-04-2|DC Chemicals

AZD-7547|AZD7547|cas 252017-04-2|DC Chemicals

AZD7545 is a novel, selective small-molecule inhibitor of PDHK2 (PDH kinase2) with an IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2 respectively.

Product Name: AZD-7547|Cat No.:DC8837|CAS: 252017-04-2|Other names: AZD 7547,AZD7547|MW: 478.87|C19H18ClF3N2O5S

AZD7545 is a novel, selective small-molecule inhibitor of PDHK2 (PDH kinase2) with an IC50 of 36.8 nM and 6.4 nM for PDHK1 and PDHK2 respectively.

For research only, not for human use!

NIBR189|NIBR 189|cas 1599432-08-2|DC Chemicals

NIBR189|NIBR 189|cas 1599432-08-2|DC Chemicals

NIBR 189 is a potent and selective EBI2 (GPR183) receptor antagonist (IC50 values are 11 and 15 nM for human and mouse EBI2 receptors respectively).

Product Name: NIBR189|Cat No.:DC8836|CAS: 1599432-08-2|Other names: NIBR-189; NIBR 189|MW: 429.31|C21H21BrN2O3

NIBR 189 is a potent and selective EBI2 (GPR183) receptor antagonist (IC50 values are 11 and 15 nM for human and mouse EBI2 receptors respectively). Exhibits selectivity for EBI2 over a panel of other receptors, enzymes and transporters. Blocks oxysterol-induced migration of U937 monocyte cells. Orally bioavailable.

For research only, not for human use!

1-Methoxy PMS|cas 65162-13-2|DC Chemicals

1-Methoxy PMS|cas 65162-13-2|DC Chemicals

1-Methoxy PMS is an electron mediator for NAD(P)H-tetrazolium salt.

Product Name: 1-Methoxy PMS|Cat No.:DC8835|CAS: 65162-13-2|Other names: 1-Methoxy-5-methylphenazinium methylsulfate|MW: 336.36|C15H16N2O5S

1-Methoxy PMS is easily dissolved by water and alcohol. Its redox potential is +63 mV. Though phenazinium methylsulfate (PMS) is commonly used as an electron carrier for NADH-tetrazolium, the stability of PMS is very poor. However, 1-Methoxy PMS solution can be stored at room temperature for over 3 months without protection from light. An electron of NAD(P)H is transfered by 1-Methoxy PMS to tetrazolium salt (Reaction Scheme). Therefore, it is a useful reagent for NAD(P)H-tetrazolium-based assay systems.

For research only, not for human use!

HZ-1157|HZ1157|CAS 1009734-33-1|DC Chemicals

HZ-1157|HZ1157|CAS 1009734-33-1|DC Chemicals

HZ-1157 is a novel potent inhibitor of HCV NS3/4A protease; Potent Dengue virus inhibitor

Product Name: HZ-1157|Cat No.:DC8834|CAS: 1009734-33-1|Other names: HZ 1157,HZ1157|MW: 232.28|C12H16N4O

HZ-1157 is a novel potent inhibitor of HCV NS3/4A protease; Potent Dengue virus inhibitor

For research only, not for human use!

Desmethyl VS-5584|CAS 1246535-95-4|DC Chemicals

Desmethyl VS-5584|CAS 1246535-95-4|DC Chemicals

Desmethyl VS-5584 is a PI3K/mTOR kinase inhibitor

Product Name: Desmethyl VS-5584|Cat No.:DC8833|CAS: 1246535-95-4|Other names: Desmethyl VS 5584, Desmethyl VS5584|MW: 340.38|C16H20N8O

Desmethyl VS-5584 is a PI3K/mTOR kinase inhibitor

For research only, not for human use!

Clemizole||CAS 442-52-4|DC Chemicals

Clemizole||CAS 442-52-4|DC Chemicals

Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.

Product Name: Clemizole (free base)|Cat No.:DC8832|CAS: 442-52-4|Other names: PKI1313,PKI 1313|MW: 325.84|C19H20ClN3

Clemizole is a H1 histamine receptor antagonist.Recently, researchers have identified that clemizole hydrochloride can inhibit NS4B's RNA binding and hepatitis C virus (HCV) replication.

For research only, not for human use!

RKI-1313|PKI1313|CAS 1342276-76-9|DC Chemicals

RKI-1313|PKI1313|CAS 1342276-76-9|DC Chemicals

RKI-1313 is the negative control for RKI-1447 which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer

Product Name: RKI-1313|Cat No.:DC8831|CAS: 1342276-76-9|Other names: PKI1313,PKI 1313|MW: 340.4|C17H16N4O2S

RKI-1313 is the negative control for RKI-1447 which is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer

For research only, not for human use!

Betahistine|CAS 5638-76-6|DC Chemicals

Betahistine|CAS 5638-76-6|DC Chemicals

Betahistine is a strong affinity histamine H3 receptor antagonist and weak affinity agonist of histamine H1 receptors.

Product Name: Betahistine|Cat No.:DC8830|CAS: 5638-76-6|Other names: |MW: 136.19|C8H12N2

Betahistine is a strong affinity histamine H3 receptor antagonist and weak affinity agonist of histamine H1 receptors.

For research only, not for human use!

Betahistine EP Impurity C| CAS 5452-87-9|DC Chemicals

Betahistine EP Impurity C| CAS 5452-87-9|DC Chemicals

N-Methyl-N,N-bis(2-pyridylethyl)amine is used as a reagent in the preparation of copper pyridylmethylethylenediamine dicyanamido polymeric complexes.

Product Name: Betahistine EP Impurity C|Cat No.:DC8829|CAS: 5452-87-9|Other names: |MW: 241.33|C15H19N3

For research only, not for human use!

HDAC inhibitor IV| CAS 537034-15-4|DC Chemicals

HDAC inhibitor IV| CAS 537034-15-4|DC Chemicals

HDAC inhibitor IV is a cell-permeable pimeloylanilide compound that acts as a FXN- (frataxin gene) specific HDAC (histone deacetylase) inhibitor.

Product Name: HDAC inhibitor IV|Cat No.:DC8828|CAS: 537034-15-4|Other names: Histone Deacetylase Inhibitor IV|MW: 325.4|C19H23N3O2

HDAC inhibitor IV is a cell-permeable pimeloylanilide compound that acts as a FXN- (frataxin gene) specific HDAC (histone deacetylase) inhibitor. Reverses the silencing of FXN transcription in FRDA (Friedreich's ataxia) cells (~3-fold increase of FXN mRNA at 5 µM in primary FRDA lymphocytes and ~3-fold frataxin expression in FRDA cell line at 2.5 µM) due to hypoacetylation of histones H3 and H4 by increasing acetylation at H3K14, H4K5 and H4K12, without significant changes in acetylation at H3K9, H4K8 and H4K16. In comparison, Trichostatin-A and SAHA, two other commonly used HDAC inhibitors, exhibit no effect on FXN transcription.

For research only, not for human use!

Didox|cas 69839-83-4|DC Chemicals

Didox|cas 69839-83-4|DC Chemicals

Didox is a simple, synthetic antioxidant that has been found to reduce the levels of oxidative injury markers.

Product Name: Didox|Cat No.:DC8827|CAS: 69839-83-4|Other names: |MW: 169.13|C7H7NO4

Didox is a simple, synthetic antioxidant that has been found to reduce the levels of oxidative injury markers. Studies have also shown that didox increases the radiosensitivity of cancer cells by inhibition of ribonucleotide reductase, resulting in a reduction of bcl-2 mediated apoptosis resistance.

For research only, not for human use!

DB07268|cas 929007-72-7|DC Chemicals

DB07268|cas 929007-72-7|DC Chemicals

DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM.

Product Name: DB07268|Cat No.:DC8826|CAS: 929007-72-7|Other names: DB 07268,DB07268,DB-07268|MW: 321.33|C17H15N5O2

DB07268 is a potent and selective JNK1 inhibitor with an IC50 value of 9 nM. This compound has some degree of selectivity over quite a few kinases with the exceptions of CHK1, CK2, and PLK. Although compound 2b(DB-07268) shows submicromolar potency against these three kinases, it still appears to exhibit at least 70- to 90-fold greater potency against JNK1 than CHK1, CK2, and PLK.

For research only, not for human use!

Dutasteride|CAS 164656-23-9|DC Chemicals

Dutasteride|CAS 164656-23-9|DC Chemicals

Dutasteride is a 5-α-reductase inhibitor that inhibits the conversion of testosterone into dihydrotestosterone (DHT). 

Product Name: Dutasteride|Cat No.:DC8825|CAS: 164656-23-9|Other names: GI 198745|MW: 528.53|C27H30F6N2O2

Dutasteride is a 5-α-reductase inhibitor that inhibits the conversion of testosterone into dihydrotestosterone (DHT). Dutasteride inhibits both isoforms of 5-α reductase (5 α-Reductase 1/5aR1 and 5 α-Reductase 2/5aR2) to a similar extent (IC50 6nmol/l and 7 nmol/l, respectively), while finasteride only inhibits Type II. Dutasteride competed for binding the LNCaP cell AR with an IC50 approximately 1.5 μM.

For research only, not for human use!

Traxoprodil|CAS 134234-12-1|DC Chemicals

Traxoprodil|CAS 134234-12-1|DC Chemicals

Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors. 

Product Name: Traxoprodil|Cat No.:DC8824|CAS: 134234-12-1|Other names: CP-101,606,CP 101606,CP101606|MW: 327.42|C20H25NO3

Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors. Traxoprodil also acts as an NMDA glutamate antagonist and has been used to decrease levodopa-induced dyskinesia.

For research only, not for human use!

XY1|Negative control of SGC 707|DC Chemicals

XY1|Negative control of SGC 707|DC Chemicals

Negative control of SGC 707. Exhibits >3000-fold lower potency (IC50 >100 μM) compared to the active analog.

Product Name: XY1|Cat No.:DC8823|CAS: 1624117-53-8|Other names: XY1,XY-1,XY 1|MW: 297.35|C17H19N3O2

Negative control of SGC 707. Exhibits >3000-fold lower potency (IC50 >100 μM) compared to the active analog.

For research only, not for human use!

MSX-122|MSX122|cas 897657-95-3|DC Chemicals

MSX-122|MSX122|cas 897657-95-3|DC Chemicals

MSX-122 is a n orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. 

Product Name: MSX-122|Cat No.:DC8822|CAS: 897657-95-3 |Other names: MSX-122,MSX 122,MSX122|MW: 292.34|C16H16N6 

MSX-122 is a n orally bioavailable inhibitor of CXCR4 with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. CXCR4, a chemokine receptor belonging to the GPCR (G protein-coupled receptor) gene family, plays an important role in chemotaxis and angiogenesis and is upregulated in several tumor cell types; it is also a co-receptor for HIV entry into T cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Note: The chemical structure of MSX-122 is very similar to that of WZ811.

For research only, not for human use!

Etifoxine Hydrochloride (CAS 56776-32-0)|DC Chemicals

Etifoxine Hydrochloride (CAS 56776-32-0)|DC Chemicals

Etifoxine Hydrochloride is a psychotropic agent with anxiolytic and anticonvulsant activity. Etifoxine Hydrochloride is an activator of GABAA R β2 and GABAA R β3.

Product Name: Etifoxine Hydrochloride|Cat No.:DC8821|CAS: 56776-32-0|Other names: NSC 163501,Antibiotic AT-125,U 42126|MW: 337.24|C17H18Cl2N2O

Etifoxine Hydrochloride is a psychotropic agent with anxiolytic and anticonvulsant activity. Etifoxine Hydrochloride is an activator of GABAA R β2 and GABAA R β3.

For research only, not for human use!

GR148672X|CAS 263890-70-6|TGH inhibitor)|DC Chemicals

GR148672X|CAS 263890-70-6|TGH inhibitor)|DC Chemicals

GR148672X is a specific TGH inhibitor.

Product Name: GR148672X|Cat No.:DC8820|CAS: 263890-70-6|Other names: GR148672X,GR-148672X,GR 148672X|MW: 340.32|C15H11F3N2O2S

GR148672X is a specific TGH inhibitor. Using 10 μM GR148672X, there was a dramatic decrease in mobilization of stored TG and of apoB100 secretion. ApoB100 secretion was decreased by 42% (P<0.03) and apoB48 by 20% (P<0.06). GR148672X inhibited TG mass secretion by 54% (P<0.02). 

For research only, not for human use!

HM-61713 (BI-1482694)|CAS 1802181-20-9|DC Chemicals

HM-61713 (BI-1482694)|CAS 1802181-20-9|DC Chemicals

HM-61713 (BI-1482694) is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.

Product Name: HM-61713 (BI-1482694)|Cat No.:DC8819|CAS: 1802181-20-9|Other names: NSC 163501,Antibiotic AT-125,U 42126|MW: |

HM61713, also known as BI 1482694, is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity. EGFR inhibitor HM61713 binds to and inhibits mutant forms of EGFR, thereby leading to cell death of EGFR-expressing tumor cells.

For research only, not for human use!

Acivicin|cas 42228-92-2|DC Chemicals

Acivicin|cas 42228-92-2|DC Chemicals

Acivicin is a glutamine analog that irreversibly inhibits glutamine-dependent amidotransferases involved in nucleotide and amino acid biosynthesis (Kis = 10 and 560 μM for anthranilate synthase and glutamate synthase, respectively).

Product Name: Acivicin|Cat No.:DC8818|CAS: 42228-92-2|Other names: NSC 163501,Antibiotic AT-125,U 42126|MW: 178.6|C5H7ClN2O3

Acivicin is a glutamine analog that irreversibly inhibits glutamine-dependent amidotransferases involved in nucleotide and amino acid biosynthesis (Kis = 10 and 560 μM for anthranilate synthase and glutamate synthase, respectively).It also reversibly inhibits γ-glutamyl transpeptidase.Acividin has been used to elucidate aspects of glutathione metabolism and has known anti-tumorigenic activity.

For research only, not for human use!

Icotinib Hydrochloride|cas 1204313-51-8|DC Chemicals

Icotinib Hydrochloride|cas 1204313-51-8|DC Chemicals

Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).

Product Name: Icotinib Hydrochloride|Cat No.:DC8817|CAS: 1204313-51-8|Other names: BPI-2009H|MW: 427.88|C22H22ClN3O4

Icotinib Hcl(BPI-2009H) is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC(50) of 5 nM, including it's mutants of EGFR(L858R), EGFR(L861Q), EGFR(T790M) and EGFR(T790M, L858R).

For research only, not for human use!

ARS-853|ARS853|KRAS-G12C inhibitor|DC Chemicals

ARS-853|ARS853|KRAS-G12C inhibitor|DC Chemicals

ARS-853 is a selective, covalent inhibitor of KRAS-G12C that inhibits mutant KRAS driven signaling by binding to the GDP bound oncoprotein and preventing activation.

Product Name: ARS-853|Cat No.:DC8816|CAS: N/A|Other names: ARS853,ARS 853|MW: 432.94|C22H29ClN4O3

ARS-853 is a selective, covalent inhibitor of KRAS-G12C that inhibits mutant KRAS driven signaling by binding to the GDP bound oncoprotein and preventing activation.

For research only, not for human use!

Motolimod (VTX-2337)|CAS 442908-10-3|DC Chemicals

Motolimod (VTX-2337)|CAS 442908-10-3|DC Chemicals

Motolimod (VTX-2337) is a novel TLR8 agonist that activates NK cells and augments ADCC.

Product Name: Motolimod (VTX-2337)|Cat No.:DC8815|CAS: 926927-61-9|Other names: VTX 2337,VTX2337|MW: 458.6|C28H34N4O2

VTX-2337 is a novel small-molecule TLR8 agonist that activates monocytes, DCs, and NK cells. Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where a polymorphism in FcγR3A limits clinical efficacy.

For research only, not for human use!

Vipadenant|CAS 442908-10-3|DC Chemicals

Vipadenant|CAS 442908-10-3|DC Chemicals

Vipadenant(BIIB-014) is an adenosine A2a antagonist with Ki of 1.3 nM; less potent for A1(Ki=69 nM).

Product Name: Vipadenant|Cat No.:DC8814|CAS: 442908-10-3|Other names: BIIB-014,BIIB 014,BIIB014|MW: 321.34|C16H15N7O

Vipadenant showed excellent binding affinity for A2A and had modest selectivity against A1 and A2B (Ki = 63 nM), while it showed good selectivity against A3 (Ki = 1005 nM). Vipadenant was able to increase contralateral rotations in 6-OHDA lesioned rats when dosed orally in combination with apomorphine at 3 and 10 mg/kg.

For research only, not for human use!

TD-4208|TD4208|CAS 864750-70-9|DC Chemicals

TD-4208|TD4208|CAS 864750-70-9|DC Chemicals

TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration of action in preclinical models of bronchoconstriction.

Product Name: TD-4208|Cat No.:DC8813|CAS: 864750-70-9|Other names: TD 4208,TD4208|MW: 597.75|C35H43N5O4

TD-4208 is a novel and potent muscarinic receptor antagonist that has a high affinity and long residence time at the M3 receptor, and demonstrates in vitro kinetic selectivity for M3 over M2 muscarinic receptor subtype and no meaningful off-target activity . TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration of action in preclinical models of bronchoconstriction.  It is currently in development for maintenance treatment of airflow obstruction in patients with COPD. 

For research only, not for human use!

TD-4208|TD4208|CAS 864750-70-9|DC Chemicals

TD-4208|TD4208|CAS 864750-70-9|DC Chemicals

TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration of action in preclinical models of bronchoconstriction.

Product Name: TD-4208|Cat No.:DC8813|CAS: 864750-70-9|Other names: TD 4208,TD4208|MW: 597.75|C35H43N5O4

TD-4208 is a novel and potent muscarinic receptor antagonist that has a high affinity and long residence time at the M3 receptor, and demonstrates in vitro kinetic selectivity for M3 over M2 muscarinic receptor subtype and no meaningful off-target activity . TD-4208 is a potent and selective inhaled muscarinic antagonist with functional lung selectivity and long duration of action in preclinical models of bronchoconstriction.  It is currently in development for maintenance treatment of airflow obstruction in patients with COPD. 

For research only, not for human use!

LJI-308|CAS 1627709-94-7|RSK inhibitor|DC Chemicals

LJI-308|CAS 1627709-94-7|RSK inhibitor|DC Chemicals

LJI308 is a selective and potent RSK inhibitor.

Product Name: LJI-308|Cat No.:DC8812|CAS: 1627709-94-7|Other names: LJI-308,LJI 308，LJI308|MW: 368.38|C21H18F2N2O2

LJI308 is a selective and potent RSK inhibitor. Structural analysis confirms binding of LJH685 to the RSK2 N-terminal kinase ATP-binding site and reveals that the inhibitor adopts an unusual nonplanar conformation that explains its excellent selectivity for RSK family kinases. LJH685 and LJI308 efficiently inhibit RSK activity in vitro and in cells. Furthermore, cellular inhibition of RSK and its phosphorylation of YB1 on Ser102 correlate closely with inhibition of cell growth, but only in an anchorage-independent growth setting, and in a subset of examined cell lines. Thus, RSK inhibition reveals dynamic functional responses among the inhibitor-sensitive cell lines, underscoring the heterogeneous nature of RSK dependence in cancer.

For research only, not for human use!

LJH-685|CAS 1627710-50-2|RSK inhibitor|DC Chemicals

LJH-685|CAS 1627710-50-2|RSK inhibitor|DC Chemicals

LJH685 is a selective and potent RSK inhibitor.

Product Name: LJH-685|Cat No.:DC8811|CAS: 1627710-50-2|Other names: LJH-685,LJH 685,LJH685|MW: 381.42|C22H21F2N3O

LJH685 is a selective and potent RSK inhibitor. Structural analysis confirms binding of LJH685 to the RSK2 N-terminal kinase ATP-binding site and reveals that the inhibitor adopts an unusual nonplanar conformation that explains its excellent selectivity for RSK family kinases. LJH685 and LJI308 efficiently inhibit RSK activity in vitro and in cells. Furthermore, cellular inhibition of RSK and its phosphorylation of YB1 on Ser102 correlate closely with inhibition of cell growth, but only in an anchorage-independent growth setting, and in a subset of examined cell lines. Thus, RSK inhibition reveals dynamic functional responses among the inhibitor-sensitive cell lines, underscoring the heterogeneous nature of RSK dependence in cancer.

For research only, not for human use!

GW 5074|GW5074|CAS 220904-83-6|DC Chemicals

GW 5074|GW5074|CAS 220904-83-6|DC Chemicals

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

Product Name: GW-5074|Cat No.:DC8810|CAS: 220904-83-6|Other names: GW 5074,GW-5074,GW5074|MW: 520.94|C15H8Br2INO2

GW5074 is a potent and specific inhibitor of c-Raf with IC50 of 9 nM and has no effect of MKK6, MKK7, p38 MAP kinase and cdks in vitro. However, treatment of neuronal cultures with GW5074 permits accumulation of activating modifications on c-Raf and also B-Raf. The inhibition of LK-induced apoptosis by GW5074 in cerebellar granule neurons is not MEK-ERK-dependent. GW5074 delays down-regulation of Akt activity but inhibits apoptosis by an Akt-independent mechanism. GW5074 affects Ras, nuclear factor-kappa B and c-jun. GW5074 inhibits cell death caused by neurotoxins in granule cells and other neuronal types.

in vivo: GW5074 is protective in an in vivo experimental model of Huntington’s disease. GW5074 (5 mg/Kg) completely prevented extensive bilateral striatal lesions induced by 3-NP in mice. GW5074 suppresses sidestream smoke-induced airway hyperresponsiveness in mice.

For research only, not for human use!

GW 5074|GW5074|CAS 220904-83-6|DC Chemicals

GW 5074|GW5074|CAS 220904-83-6|DC Chemicals

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

Product Name: GW-5074|Cat No.:DC8810|CAS: 220904-83-6|Other names: GW 5074,GW-5074,GW5074|MW: 520.94|C15H8Br2INO2

GW5074 is a potent and specific inhibitor of c-Raf with IC50 of 9 nM and has no effect of MKK6, MKK7, p38 MAP kinase and cdks in vitro. However, treatment of neuronal cultures with GW5074 permits accumulation of activating modifications on c-Raf and also B-Raf. The inhibition of LK-induced apoptosis by GW5074 in cerebellar granule neurons is not MEK-ERK-dependent. GW5074 delays down-regulation of Akt activity but inhibits apoptosis by an Akt-independent mechanism. GW5074 affects Ras, nuclear factor-kappa B and c-jun. GW5074 inhibits cell death caused by neurotoxins in granule cells and other neuronal types.

in vivo: GW5074 is protective in an in vivo experimental model of Huntington’s disease. GW5074 (5 mg/Kg) completely prevented extensive bilateral striatal lesions induced by 3-NP in mice. GW5074 suppresses sidestream smoke-induced airway hyperresponsiveness in mice.

For research only, not for human use!

GW 5074|GW5074|CAS 220904-83-6|DC Chemicals

GW 5074|GW5074|CAS 220904-83-6|DC Chemicals

GW 5074 is a potent, selective and cell-permeable c-Raf1 kinase inhibitor (IC50 = 9 nM); displays ≥ 100-fold selectivity for raf kinase over CDK1, CDK2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms.

Product Name: GW-5074|Cat No.:DC8810|CAS: 220904-83-6|Other names: GW 5074,GW-5074,GW5074|MW: 520.94|C15H8Br2INO2

GW5074 is a potent and specific inhibitor of c-Raf with IC50 of 9 nM and has no effect of MKK6, MKK7, p38 MAP kinase and cdks in vitro. However, treatment of neuronal cultures with GW5074 permits accumulation of activating modifications on c-Raf and also B-Raf. The inhibition of LK-induced apoptosis by GW5074 in cerebellar granule neurons is not MEK-ERK-dependent. GW5074 delays down-regulation of Akt activity but inhibits apoptosis by an Akt-independent mechanism. GW5074 affects Ras, nuclear factor-kappa B and c-jun. GW5074 inhibits cell death caused by neurotoxins in granule cells and other neuronal types.

in vivo: GW5074 is protective in an in vivo experimental model of Huntington’s disease. GW5074 (5 mg/Kg) completely prevented extensive bilateral striatal lesions induced by 3-NP in mice. GW5074 suppresses sidestream smoke-induced airway hyperresponsiveness in mice.

For research only, not for human use!

Bedaquiline fumarate|CAS 845533-86-0|DC Chemicals

Bedaquiline fumarate|CAS 845533-86-0|DC Chemicals

Bedaquiline fumarate(TMC207; R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis.

Product Name: Bedaquiline fumarate|Cat No.:DC8809|CAS: 845533-86-0|Other names: TMC-207,TMC207,TMC 207|MW: 671.58|C36H35BrN2O6

Preclinical studies have shown the efficacy of bedaquiline in terms of reduction in bacterial load and treatment duration. Phase II clinical studies have established the safety, tolerability and earlier sputum conversion time in patients with MDR-TB. In 2012 FDA approved bedaquiline for treatment of MDR-TB and XDR-TB. Bedaquiline possesses a unique mechanism of action that disrupts the activity of the mycobacterial adenosine triphosphate synthase. Clinical trials have been conducted evaluating the use of bedaquiline in combination with a background regimen for the treatment of adults with pulmonary MDR-TB. Bedaquiline has an excellent in vitro activity against Mycobacterium tuberculosis, including multidrug resistant M tuberculosis; however, its side effect profile limits its use against MDR-TB when no other effective regimen can be provided.

For research only, not for human use!

BX-513 hydrochloride|CAS 193542-65-3|DC Chemicals

BX-513 hydrochloride|CAS 193542-65-3|DC Chemicals

BX-513 hydrochloride inhibits MIP-1α-induced intracellular calcium mobilization (IC50 = 2.5 μM).

Product Name: BX-513 hydrochloride|Cat No.:DC8808|CAS: 193542-65-3|Other names: BX513,BX 513|MW: 376.25|C16H20Cl2FN3O2

BX-513 hydrochloride inhibits MIP-1α-induced intracellular calcium mobilization (IC50 = 2.5 μM). Selective CCR1 receptor antagonist (Ki values are 0.04, > 10, > 10 and > 10 nM for CCR1, CCR5, CXCR2 and CXCR4 receptors respectively). A full inverse agonist at US28, a HCMV-encoded chemokine receptor.

For research only, not for human use!

Retigabine 2HCl|CAS 150812-13-8|DC Chemicals

Retigabine 2HCl|CAS 150812-13-8|DC Chemicals

Retigabine 2Hcl (Ezogabine; D23129) is a Kv7.2-7.5 (KCNQ2-5) neuronal potassium channel opener witrh anticonvulsant activity.

Product Name: Retigabine dihydrochloride|Cat No.:DC8807|CAS: 150812-13-8|Other names: D 20443 dihydrochloride; D-20443 dihydrochloride; D20443 dihydrochloride|MW: 376.25|C16H20Cl2FN3O2

Retigabine (D-23129) is a novel antiepileptic compound with broad spectrum and potent anticonvulsant properties, both in vitro and in vivo. The compound was shown to activate a K+ current in neuronal cells. The pharmacology of the induced current displays concordance with the published pharmacology of the M-channel, which recently was correlated to the KCNQ2/3 K+ channel heteromultimere. Retigabine is a novel anticonvulsant with an unknown mechanism of action. Application of 10 μM retigabine to oocytes expressing the KCNQ2/3 heteromeric channel shifted both the activation threshold and voltage for half-activation by approximately 20 mV in the hyperpolarizing direction, leading to an increase in current amplitude at test potentials between ?80 mV and +20 mV. Retigabine also had a marked effect on KCNQ current kinetics, increasing the rate of channel activation but slowing deactivation at a given test potential.  Retigabine shifted the voltage dependence of channel activation with an EC50value of 1.6 ± 0.3 μM (slope factor was 1.2 ± 0.1,n = 4 to 5 cells per concentration). Retigabine (0.1 to 10 μM) also slowed the rate of channel deactivation, predominantly by increasing the contribution of a slowly deactivating tail current component.  Administration of centrally acting M-channel opener retigabine (2.5 and 7.5 mg/kg) can dose-dependently raise the head withdrawal threshold of mechanical allodynia, and this analgesic effect can be reversed by the specific KCNQ channel blocker XE991 (3 mg/kg). Food intake was increased significantly by the administration of retigabine (2.5 and 7.5 mg/kg), and this effect was reversed by XE991 (3 mg/kg). Furthermore, intracerebralventricular injection of retigabine further confirmed the analgesic effect of central retigabine on inflammatory TMJ. Retigabine exerted both antiepileptogenic and antiictogenic effects under conditions of rapid kindling model.

For research only, not for human use!

NS-398|NS398|CAS 123653-11-2|DC Chemicals

NS-398|NS398|CAS 123653-11-2|DC Chemicals

NS-398 is a selective inhibitor of cyclooxygenase-2 (COX-2).

Product Name: NS-398|Cat No.:DC8806|CAS: 123653-11-2|Other names: NS-398,NS 398,NS398|MW: 314.4|C13H18N2O5S

NS-398 is a selective inhibitor of cyclooxygenase-2 (COX-2). The IC50 values for human recombinant COX-1 and -2 are 75 and 1.77 µM, respectively.The IC50 values for ovine COX-1 and -2 are 220 and 0.15 µM, respectively.

For research only, not for human use!

MS049|MS-049|DC Chemicals

MS049|MS-049|DC Chemicals

MS049 is a potent and selective inhibitor of PRMT4 and PRMT6 that is active in cells. 

Product Name: MS049 (hydrochloride)|Cat No.:DC8805|CAS: N/A|Other names: MS049,MS-049,MS 049 |MW: 321.29|C15H24N2O.2HCl

For research only, not for human use!

APD-597|JNJ-38431055|CAS 897732-93-3|DC Chemicals

APD-597|JNJ-38431055|CAS 897732-93-3|DC Chemicals

APD597(JNJ-38431055) is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119.

Product Name: APD-597|Cat No.:DC8804|CAS: 897732-93-3|Other names: JNJ-38431055; APD-597; APD 597; JNJ38431055; JNJ 38431055|MW: 479.55|C21H29N5O6S

APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes, with EC50 of 46 nM for hGPR119. The design and synthesis of a second generation GPR119-agonist clinical candidate for the treatment of diabetes is described. APD597 was selected for preclinical development based on a good balance between agonist potency, intrinsic activity and in particular on its good solubility and reduced drug-drug interaction potential.

For research only, not for human use!

L-778123|cas 253863-00-2|DC Chemicals

L-778123|cas 253863-00-2|DC Chemicals

L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.

Product Name: L-778123 HCl|Cat No.:DC8803|CAS: 253863-00-2|Other names: L-778123,L 778123,L778123|MW: 405.88|C22H20ClN5O 

L-778123 is an inhibitor of FPTase and GGPTase-I, which was developed in part because it can completely inhibit Ki-Ras prenylation. The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed .

For research only, not for human use!

Ansamitocin P-0|Maytansinol|DC Chemicals

Ansamitocin P-0|Maytansinol|DC Chemicals

Product Name: Maytansinol(Ansamitocin P-0)|Cat No.:DC8802|CAS: 57103-68-1|Other names: Maytansinol, Antibiotic C 15003P|MW: 565.05|C28H37ClN2O8

For research only, not for human use!

Cinacalcet (AMG-073)|cas 226256-56-0|DC Chemicals

Cinacalcet (AMG-073)|cas 226256-56-0|DC Chemicals

Cinacalcet(AMG-073) is an orally active, second-generation calcimimetic compound; AMG 073 represents a new class of compounds for the treatment of hyperparathyroidism.

Product Name: Cinacalcet (AMG-073)|Cat No.:DC8801|CAS: 226256-56-0|Other names: AMG 073; AMG073; AMG-073|MW: 357.41|C22H22F3N

Cinacalcet is the only calcimimetic approved for HPT secondary to chronic kidney disease (CDK), parathyroid carcinoma, and, in some countries, primary HPT. Clinical trials showed that cinacalcet reduced PTH and calcemia both in CDK and primary HPT, lowering the risk of bone fractures, surgery, and cardiovascular complications in the former patients. Long-term safety and pharmacoeconomics have to be fully tested yet. Few both in vitro and in vivo studies showed an association between Arg990Gly-CASR polymorphism and cinacalcet sensitivity, though in patients with severe CASR inactivating mutations the drug substantially retained its positive clinical effects.

For research only, not for human use!

Solifenacin Succinate|cas 242478-38-2|DC Chemicals

Solifenacin Succinate|cas 242478-38-2|DC Chemicals

Solifenacin Succinate(YM905; Vesicare) is a muscarinic receptor antagonist.

Product Name: Solifenacin Succinate|Cat No.:DC8800|CAS: 242478-38-2|Other names: Vesicare; YM905; YM-905; YM 905|MW: 480.55|C27H32N2O6

For research only, not for human use!

Avanafil(TA-1790) |cas 330784-47-9|DC Chemicals

Avanafil(TA-1790) |cas 330784-47-9|DC Chemicals

Avanafil(TA-1790) is a potent and highly selective phosphodiesterase-5(PDE-5) inhibitor(IC50=5.2 nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11.

Product Name: Avanafil(TA-1790)|Cat No.DC8799|CAS: 330784-47-9|Other names: |MW: 483.95|C23H26ClN7O3

Avanafil is highly selective toward PDE5 and against all other PDE isozymes tested. Lower selectivity against PDE1, PDE6, and PDE11 is consistent with results from randomized, placebo-controlled, phase 3 trials in which musculoskeletal and hemodynamic adverse events were reported in <2% of patients and no color vision-related abnormalities were reported with avanafil doses up to 200mg once daily . Intraduodenal doses of avanafil or sildenafil (0.1 and 1 mg/kg) potentiated the AUC of nitroglycerin induced hypotension. However, the potentiating effect of avanafil at 1 mg/kg was significantly weaker than that of sildenafil (p <0.05)

For research only, not for human use!

Acotiamide|cas 185106-16-5|DC Chemicals

Acotiamide|cas 185106-16-5|DC Chemicals

Acotiamide acts as an acetylcholinesterase inhibitor

Product Name: Acotiamide|Cat No.:DC8798|CAS: 185106-16-5|Other names: |MW: 450.55|C21H30N4O5S

For research only, not for human use!

Lacosamide|cas 175481-36-4|DC Chemicals

Lacosamide|cas 175481-36-4|DC Chemicals

Lacosamide (Vimpat; Erlosamide) is a medication developed for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.

Product Name: Lacosamide|Cat No.:DC8797|CAS: 175481-36-4|Other names: |MW: 250.29|C13H18N2O3

Lacosamide is a functionalized amino acid that produces activity in the maximal electroshock seizure (MES) test, that, like some other antiepileptic drugs (AEDs), are believed to act through voltage-gated sodium channels. Lacosamide enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels. This inactivation prevents the channel from opening, helping end the action potential. Many antiepileptic drugs, like carbamazepine or lamotrigine, slow the recovery from inactivation and hence reduce the ability of neurons to fire action potentials.

For research only, not for human use!

Minodronic acid monohydrate| Ono-5920|DC Chemicals

Minodronic acid monohydrate| Ono-5920|DC Chemicals

Product Name: Minodronic acid monohydrate|Cat No.:DC8796|CAS: 155648-60-5|Other names: |MW: 322.15|C9H12N2O7P2

For research only, not for human use!

NVP-ACC-789|cas 300842-64-2|DC Chemicals

NVP-ACC-789|cas 300842-64-2|DC Chemicals

NVP-ACC789 is an inhibitor of VEGFR-2 (FLK-1/KDR).

Product Name: NVP-ACC-789|Cat No.:DC8794|CAS: 300842-64-2|Other names: ACC-789, ZK-202650, NVP-ACC-789,ACC789,ACC 789|MW: 405.3|C21H17BrN4

For research only, not for human use!

Edoxaban tosylate monohydrate|cas 1229194-11-9|DC Chemicals

Edoxaban tosylate monohydrate|cas 1229194-11-9|DC Chemicals

Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention

Product Name: Edoxaban tosylate monohydrate|Cat No.:DC8793|CAS: 1229194-11-9|Other names: |MW: 738.27|C31H40ClN7O8S2

For research only, not for human use!

Sorafenib (BAY-43-9006)From supplier |DC Chemicals

Sorafenib (BAY-43-9006)From supplier |DC Chemicals

Sorafenib(BAY 43-9006) is a potent inhibitor of Raf-1 with IC50 values of 6 nM, 22 nM and 90 nM for Raf-1, B-Raf, and VEGFR2 respectively, BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro.

Product Name: nmj8nmj8nmj8|Cat No.:DC8791|CAS: 284461-73-0|Other names: Bay 43-9006,Bay43-9006|MW: 464.83|C21H16ClF3N4O3

Sorafenib tosylate is the tosylate salt of sorafenib, a synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis. Check  For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

 For the detailed information about the solubility of Sorafenib (BAY-43-9006) in water, the solubility of Sorafenib (BAY-43-9006) in DMSO, the solubility of Sorafenib (BAY-43-9006) in PBS buffer, the animal experiment（test） of Sorafenib (BAY-43-9006),the in vivo,in vitro and clinical trial test of Sorafenib (BAY-43-9006),the cell experiment（test） of Sorafenib (BAY-43-9006),the IC50, EC50 and Affinity of Sorafenib (BAY-43-9006), please contact DC Chemicals.

For research only, not for human use!

Pirfenidone(AMR69)|cas 53179-13-8|DC Chemicals

Pirfenidone(AMR69)|cas 53179-13-8|DC Chemicals

Pirfenidone(AMR69) is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Phase 3.

Product Name: Pirfenidone(AMR69)|Cat No.:DC8792|CAS: 53179-13-8|Other names: |MW: 185.22|C12H11NO

For research only, not for human use!

L67|DNA ligase inhibitor| CAS 325970-71-6|DC Chemicals

L67|DNA ligase inhibitor| CAS 325970-71-6|DC Chemicals

L67 is a novel, competitive human DNA ligase inhibitor, inhibits DNA ligases I and III with IC50 of 10 μM and 10 μM.

Product Name: L67|Cat No.:DC8790|CAS: 325970-71-6|Other names: DNA Ligase Inhibitor; L-67; L 67|MW: 486.11|C16H14Br2N4O4

L67 is a novel, competitive human DNA ligase inhibitor, inhibits DNA ligases I and III with IC50 of 10 μM and 10 μM. L67 significantly increases the cytotoxicity of DNA damaging agents.[1] L67 also inhibits cell proliferation.

For research only, not for human use!